2019 |
Zeineb Laghmani |
Referral under Article 31 of Directive 2001/83/EC: An example of vancomycin-containing medicinal products *** |
|
|
2019 |
Dr. Tanja Lidy |
Drug shortages for supply-relevant medicinal products exemplified by vaccines - Notifications, reasons and effects *** |
|
|
2019 |
Amelie Link |
Herausforderung Zusatznutzennachweis bei seltenen Treibermutationen - Nutzenbewertungsverfahren nach §35a SGB V zum NSCLC mit ALK- oder ROS1-Treibermutation (2012 bis 2018) *** |
|
|
2019 |
Astrid Maeder-Jeske |
Antimicrobial Resistance - An analysis of the current situation with a special focus on policy approaches and regulations in the European Union, the United States and on the part of the WHO to prevent an escalation of the situation *** |
|
|
2019 |
Xinyu Meng |
Medical Device Regulations in the People’s Republic of China - the New Trend and the Challenges and Opportunities to European Medical Device Manufacturers *** |
|
|
2019 |
Dr. Melanie Mühlfelder |
Real-life experiences with approval of pediatric clinical trials in Germany |
|
|
2019 |
Dr. Olga Nilmayer |
Regulatory requirements concerning the manufacture and clinical use of human cornea in Germany *** |
|
|
2019 |
Stefanie Rodler |
Elemental Impurities in Drug Products: Challenges for the pharmaceutical industry in establishing limits based on ICH Q3D for alternative routes of administration *** |
|
|
2019 |
Dr. Mareike Schnaars |
Regulatory Challenges and Strategies for Allergen Products in the European Union and Canada *** |
|
|
2019 |
Caroline Schommer |
MDR's Article 117: Regulatory Strategy to Comply With the General Safety and Performance Requirements Set Out in Annex I in the Light of a Single Integral Drug Device Combination *** |
|
|
2019 |
Dr. Karim Sempf |
The Valsartan Case and its Consequences for the Global Supply of Pharmaceutical Active Ingredients |
|
|
2019 |
Theresa Sorgenfrei |
Readability and comprehensibility of package leaflets - recent efforts for improvement within the EU and a historical review *** |
|
|
2019 |
Dr. Ansgar Stüken |
The New ICH Guideline ICH S5(R3) on Reproductive Toxicology on Medicinal Products for Human Use - Opportunities and Challenges for European Non-Clinical Drug Development *** |
|
|
2019 |
Dr. Alexandra Thornagel |
Implikationen von Artikel 31-EU-Referrals in Deutschland am Beispiel von Metformin (EMEA/H/A-31/1432) und Valproat (EMEA/H/A-31/1454) *** |
|
|
2019 |
Heike Trautmann |
Regulation (EU) 2015/2283 on novel foods - Analysis of the amendments and their impact on regulatory work *** |
|
|
2019 |
Dr. Anja von Au |
Medical device safety reporting in clinical investigations and PMCF studies under the new MDR - A comparison to the current German legislation |
|
|
2019 |
Dr. Oliver Walisko |
Potency Assignment of Factor IX Medicinal Products for the Treatment of Hemophilia B: Regulatory meets Practice *** |
|
|
2019 |
Susanne Werk |
The European MDR and its potential impact on the existing German legislation on medical devices and the status of the discussion on the interpretation of several requirements of the MDR |
|
|
2019 |
Fabian Witzel |
Standardization as Key for Global Digital Health Regulatory Affairs Improvement *** |
|
|
2019 |
Dr. Nicole Woik |
Comparative analysis of the strategies for implementation of the Clinical Trials Regulation (EU) No 536/2014 in Europe *** |
|
|